Atogepant Efficacious for Patients With Chronic Migraine
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 26, 2024 -- For patients with chronic migraine (CM), with and without medication overuse, atogepant is efficacious, according to a study published online June 27 in Neurology.
Peter J. Goadsby, M.D., Ph.D., from King's College London, and colleagues examined the efficacy of atogepant for the preventive treatment of CM in participants with and without acute medication overuse. Participants had at least a one-year history of CM, ≥15 monthly headache days (MHDs), and at least eight monthly migraine days (MMDs) during the four-week baseline period, and were randomly allocated to receive placebo, atogepant 30 mg twice daily (BID), or atogepant 60 mg once daily (QD) for 12 weeks.
The researchers found that 66.2 percent of the 755 participants in the modified intent-to-treat population met the criteria for baseline acute medication overuse. The least squares mean difference (LSMD) in MMDs was -2.7 and -1.9 for atogepant 30 mg BID and atogepant 60 mg QD, respectively, from placebo. There were reductions observed in mean MHDs (LSMD, −2.8 and −2.1, respectively) and mean acute medication use days (LSMD, −2.8 and −2.6, respectively), while an increase was seen in the proportion that achieved ≥50 percent reduction in MMDs (odds ratios, 2.5 and 2.3 with atogepant 30 mg BID and atogepant 60 mg QD, respectively). The proportion of atogepant-treated participants meeting acute medication overuse criteria decreased 52.1 to 61.9 percent over 12 weeks. Patient-reported outcome measures improved with atogepant.
"Treatment with atogepant may potentially decrease the risk of developing rebound headache by reducing the use of pain medications," Goadsby said in a statement.
Several authors disclosed ties to biopharmaceutical companies, including AbbVie, which manufactures atogepant and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
No Increase Seen in Neurodevelopmental Disorders With Prenatal Triptan Use
WEDNESDAY, May 21, 2025 -- Children prenatally exposed to different triptan intensities and duration, alone or in combination with other preventive medications for migraine, do...
Ubrogepant During Prodromal Phase of Migraine Eases Symptoms
TUESDAY, May 13, 2025 -- Ubrogepant during the prodromal phase of migraine may alleviate common prodromal symptoms, according to a study published online May 12 in Nature...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.